Cited 11 times in
A phase I study of everolimus and CHOP in newly diagnosed peripheral T-cell lymphomas
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 김진석 | - |
dc.contributor.author | 양우익 | - |
dc.date.accessioned | 2018-05-10T06:40:44Z | - |
dc.date.available | 2018-05-10T06:40:44Z | - |
dc.date.issued | 2013 | - |
dc.identifier.issn | 0167-6997 | - |
dc.identifier.uri | https://ir.ymlib.yonsei.ac.kr/handle/22282913/158423 | - |
dc.description.abstract | BACKGROUND: We performed a phase I study to determine the dose and safety of everolimus as a combination chemotherapy in peripheral T-cell lymphoma (PTCL). METHODS: Four dose levels (2.5 to 10 mg) of everolimus from days 1 to 14 with CHOP (750 mg/m(2) cyclophosphamide, 50 mg/m(2) doxorubicin, and 1.4 mg/m(2) (maximum 2 mg) vincristine on day 1, and 100 mg/day prednisone on days 1 to 5) every 21 days were planned. RESULTS: Fifteen patients newly diagnosed with stage III/IV PTCL were enrolled. One of 6 patients at dose level 2 (5 mg everolimus) had grade 3 hepatotoxicity and 3 of 6 patients at level 3 (7.5 mg everolimus) had grade 4 hematologic toxicities (two grade 4 thrombocytopenia and one grade 4 neutropenia with fever lasting more than 3 days). The recommended dose of everolimus for combination was 5 mg. There were no differences in steady state trough concentrations of everolimus between cycles 1 and 2 for all three dose levels. All evaluable patients achieved response (8 complete and 6 partial). CONCLUSIONS: Everolimus (5 mg) can be safely combined with CHOP leading to a feasible and effective regimen for PTCL. The subsequent phase II is now in progress. | - |
dc.description.statementOfResponsibility | restriction | - |
dc.language | English | - |
dc.publisher | Springer | - |
dc.relation.isPartOf | INVESTIGATIONAL NEW DRUGS | - |
dc.rights | CC BY-NC-ND 2.0 KR | - |
dc.rights | https://creativecommons.org/licenses/by-nc-nd/2.0/kr/ | - |
dc.subject.MESH | Antineoplastic Combined Chemotherapy Protocols/administration & dosage* | - |
dc.subject.MESH | Antineoplastic Combined Chemotherapy Protocols/adverse effects | - |
dc.subject.MESH | Antineoplastic Combined Chemotherapy Protocols/pharmacokinetics | - |
dc.subject.MESH | Cyclophosphamide/administration & dosage | - |
dc.subject.MESH | Cyclophosphamide/adverse effects | - |
dc.subject.MESH | Cyclophosphamide/pharmacokinetics | - |
dc.subject.MESH | Doxorubicin/administration & dosage | - |
dc.subject.MESH | Doxorubicin/adverse effects | - |
dc.subject.MESH | Doxorubicin/pharmacokinetics | - |
dc.subject.MESH | Drug Administration Schedule | - |
dc.subject.MESH | Everolimus | - |
dc.subject.MESH | Humans | - |
dc.subject.MESH | Lymphoma, T-Cell, Peripheral/drug therapy* | - |
dc.subject.MESH | Lymphoma, T-Cell, Peripheral/metabolism | - |
dc.subject.MESH | Maximum Tolerated Dose | - |
dc.subject.MESH | Prednisone/administration & dosage | - |
dc.subject.MESH | Prednisone/adverse effects | - |
dc.subject.MESH | Prednisone/pharmacokinetics | - |
dc.subject.MESH | Sirolimus/administration & dosage | - |
dc.subject.MESH | Sirolimus/adverse effects | - |
dc.subject.MESH | Sirolimus/analogs & derivatives* | - |
dc.subject.MESH | Sirolimus/pharmacokinetics | - |
dc.subject.MESH | Vincristine/administration & dosage | - |
dc.subject.MESH | Vincristine/adverse effects | - |
dc.subject.MESH | Vincristine/pharmacokinetics | - |
dc.title | A phase I study of everolimus and CHOP in newly diagnosed peripheral T-cell lymphomas | - |
dc.type | Article | - |
dc.contributor.college | College of Medicine | - |
dc.contributor.department | Dept. of Internal Medicine | - |
dc.contributor.googleauthor | Seok Jin Kim | - |
dc.contributor.googleauthor | Hye Jin Kang | - |
dc.contributor.googleauthor | Jin Seok Kim | - |
dc.contributor.googleauthor | Hyeon-Seok Eom | - |
dc.contributor.googleauthor | Jooryung Huh | - |
dc.contributor.googleauthor | Young Hyeh Ko | - |
dc.contributor.googleauthor | Jongtae Lee | - |
dc.contributor.googleauthor | Dong-Seok Yim | - |
dc.contributor.googleauthor | Soo-Youn Lee | - |
dc.contributor.googleauthor | Weon Seo Park | - |
dc.contributor.googleauthor | Woo Ick Yang | - |
dc.contributor.googleauthor | Seung-Sook Lee | - |
dc.contributor.googleauthor | Cheolwon Suh | - |
dc.contributor.googleauthor | Won Seog Kim | - |
dc.identifier.doi | 10.1007/s10637-013-0015-z | - |
dc.contributor.localId | A01017 | - |
dc.contributor.localId | A02300 | - |
dc.relation.journalcode | J01184 | - |
dc.identifier.eissn | 1573-0646 | - |
dc.identifier.pmid | 23975510 | - |
dc.identifier.url | https://link.springer.com/article/10.1007%2Fs10637-013-0015-z | - |
dc.subject.keyword | Everolimus | - |
dc.subject.keyword | CHOP | - |
dc.subject.keyword | T-cell lymphoma | - |
dc.contributor.alternativeName | Kim, Jin Seok | - |
dc.contributor.alternativeName | Yang, Woo Ick | - |
dc.contributor.affiliatedAuthor | Kim, Jin Seok | - |
dc.contributor.affiliatedAuthor | Yang, Woo Ick | - |
dc.citation.volume | 31 | - |
dc.citation.number | 6 | - |
dc.citation.startPage | 1514 | - |
dc.citation.endPage | 1521 | - |
dc.identifier.bibliographicCitation | INVESTIGATIONAL NEW DRUGS, Vol.31(6) : 1514-1521, 2013 | - |
dc.identifier.rimsid | 42424 | - |
dc.type.rims | ART | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.